Has Sequenom Become the Perfect Stock?

Every investor would love to stumble upon the perfect stock. But will you ever really find a stock that provides everything you could possibly want?

One thing's for sure: You'll never discover truly great investments unless you actively look for them. Let's discuss the ideal qualities of a perfect stock, then decide if Sequenom (NASDAQ: SQNM  ) fits the bill.

The quest for perfection
Stocks that look great based on one factor may prove horrible elsewhere, making due diligence a crucial part of your investing research. The best stocks excel in many different areas, including these important factors:

  • Growth. Expanding businesses show healthy revenue growth. While past growth is no guarantee that revenue will keep rising, it's certainly a better sign than a stagnant top line.
  • Margins. Higher sales mean nothing if a company can't produce profits from them. Strong margins ensure that company can turn revenue into profit.
  • Balance sheet. At debt-laden companies, banks and bondholders compete with shareholders for management's attention. Companies with strong balance sheets don't have to worry about the distraction of debt.
  • Money-making opportunities. Return on equity helps measure how well a company is finding opportunities to turn its resources into profitable business endeavors.
  • Valuation. You can't afford to pay too much for even the best companies. By using normalized figures, you can see how a stock's simple earnings multiple fits into a longer-term context.
  • Dividends. For tangible proof of profits, a check to shareholders every three months can't be beat. Companies with solid dividends and strong commitments to increasing payouts treat shareholders well.

With those factors in mind, let's take a closer look at Sequenom.

Factor

What We Want to See

Actual

Pass or Fail?

Growth

5-year annual revenue growth > 15%

13.6%

Fail

 

1-year revenue growth > 12%

32%

Pass

Margins

Gross margin > 35%

34.2%

Fail

 

Net margin > 15%

(148.9%)

Fail

Balance sheet

Debt to equity < 50%

198.4%

Fail

 

Current ratio > 1.3

5.16

Pass

Opportunities

Return on equity > 15%

(114.2%)

Fail

Valuation

Normalized P/E < 20

NM

NM

Dividends

Current yield > 2%

0%

Fail

 

5-year dividend growth > 10%

0%

Fail

       
 

Total score

 

2 out of 9

Source: S&P Capital IQ. NM = not meaningful due to negative earnings. Total score = number of passes.

Since we looked at Sequenom last year, the company has dropped three points, reversing course from its one-point gain from 2011 to 2012. Margins fell and the company added a huge amount of debt, and the shares didn't respond well, falling about 10% over the past year.

Sequenom remains a major player in the genetic analysis and testing business. Its MaterniT21 PLUS prenatal test for Down syndrome has become a major driver of its overall revenue, even though genetic analysis still made up a majority of its revenue during the first three quarters of 2012. Getting a favorable recommendation from the American College of Obstetricians and Gynecologists for the test is a potentially huge sales driver.

The big question, though, is when Sequenom will get major insurance carriers to cover the cost of the test. Coventry Health Care (NYSE: CVH  ) changed its mind about covering the test last May. Without coverage, it will be hard for Sequenom to reach its full revenue potential.

Last month, Sequenom provided preliminary figures for its fourth quarter and the full 2012 year. Despite showing strong revenue growth, Sequenom's stock plunged on news that rival Illumina (NASDAQ: ILMN  ) would acquire privately held Verinata Health. Verinata has its own prenatal test for Down syndrome that competes against MaterniT21, and Sequenom investors fear that competitive pressure could lead to longer delays before it turns consistently profitable. With Amgen's (NASDAQ: AMGN  ) recent purchase of deCODE Genetics, Sequenom will continue to face new rivals in the space.

For Sequenom to improve, it needs to get its balance sheet under control and find ways to become profitable. With increasingly popular tests, the company certainly has potential to make money if it can establish itself well enough to get every health insurer to pony up for their cost.

Keep searching
No stock is a sure thing, but some stocks are a lot closer to perfect than others. By looking for the perfect stock, you'll go a long way toward improving your investing prowess and learning how to separate out the best investments from the rest.

Whether you choose the health-care industry or some other focus for your portfolio, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Click here to add Sequenom to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.


Read/Post Comments (2) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 07, 2013, at 1:26 PM, foolish07 wrote:

    I see you believe: One size fits all.

    A chimpanzee can use your model to evaluate stocks and get the same results.

    You used no analysis at all, just noted a few items that others had published before.

    "it needs to get its balance sheet under control"

    It is spending to grow to make those future profits.

    You are only qualified to evaluate mutual funds.

    It's a speculative stock, DUH!

  • Report this Comment On February 07, 2013, at 10:50 PM, earthunit wrote:

    LOL! TOTALLY poorly researched. Too many errors and half-truths to mention in a lifetime. CRAP article!

    I'm continuing to accumulate SQNM. Suffice it to say that as SQNM moves towards 100% "accrual" accounting (which you didn't even mention!) their sales, margin, and earnings stats will look MUCH MUCH better. It's only illusion right now that makes them look less than stellar.

Add your comment.

DocumentId: 2242178, ~/Articles/ArticleHandler.aspx, 4/21/2014 8:12:46 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement